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a b s t r a c t
Objective: Melilotus officinalis (L.) Pall. is commonly used for treating bronchitis, painful menstruation,
hemorrhoids, kidney stones, ulcers of the eyes, earache, and hardening and swelling of uterus. The
European Medicines Agency reported the use of M. officinalis orally against stomach ache, gastric ulcer,
and disorders of the liver and uterus in folk medicine. The present study aimed to appraise the activity of
M. (L.) Pall. aerial parts in endometriosis rat model.
Materials and methods: The endometriosis rat model was used to evaluate the potential activity of
M. officinalis aerial parts based on its folkloric usage. The aerial parts of M. officinalis were extracted with
n-hexane, ethyl acetate (EtOAc), and methanol (MeOH), respectively. The adhesion scores, endometrial
foci areas, and cytokine levels were measured in all treated groups. After the biological activity studies,
phytochemical studies were performed on the active extract and the fractions obtained from the active
extract.
Results: The MeOH extract significantly decreased the endometrial foci areas and cytokine levels in rats
with endometriosis. Fractionation was performed on the MeOH extract to achieve bioactive molecules.
Following the fractionation, the fractions obtained from the MeOH extract were tested. Fraction C
showed the highest activity in the rat endometriosis model. Phytochemical investigation of the active
fraction (Fraction C) resulted in isolation and elucidation of some quercetin and kaempferol glucoside
derivatives.
Conclusion: Fraction C obtained from the MeOH extract of M. officinalis showed the highest activity,
yielding four glycosylated flavonoids.
© 2020 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Melilotus officinalis (L.) Pall. (Fabaceae) is native in Europe and
Asia and known as “yellow melilot, yellow sweet clover, and me-
dicinal sweet clover” [1,2]. M. officinalis is commonly used for
treating hemorrhoids, bronchitis, kidney stones, painful menstru-
ation, earache, ulcers of the eyes, and hardening and swelling of
uterus [3,4]. The European Medicines Agency reported the tradi-
tional use of M. officinalis orally against stomach ache, gastric ulcer,
and complaints of liver and uterus [5].
Biological activity studies demonstrated the antioxidant, anti-
inflammatory, and antiproliferative effects of M. officinalis [6,7].
Some studies showed that this plant prevented skin aging, pro-
moted tissue regeneration, and reduced fat deposition [8]. Previous
studies about phytochemical profile of M. officinalis reported that
M. officinalis contains kaempferol, quercetin, and coumarin de-
rivatives [3e5,9].
Endometriosis is defined as the condition in which a tissue
resembling the uterine mucous membrane, or endometrium, if
found outside of the uterus. It can develop in the uterine ligaments,
ovaries, pelvic peritoneum, rectovaginal septum, covering the sig-
moid colon, uterus, rectum, tubes or bladder, umbilicus, laparotomy
and episiotomy scars, tubal stumps, hernial sacs, appendix, cervix,
vagina, vulva or lymph glands [10]. The incidence of endometriosis
has increased in the last few decades. This increase is most probably
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due to the growing use of laparoscopy in gynecologic practice,
making it easier to diagnose endometriosis. Endometriosis is
detected in 5%e15% of laparotomies and laparoscopies performed
on 30% of women with chronic pelvic pain and in up to 40% of
infertile women [11].
The present study describes the effects of extracts/fractions
obtained from the aerial parts of M. officinalis in a surgically-
induced endometriosis rat model by evaluating adhesion scores
of endometriotic implants, areas of endometriotic foci, and cyto-
kine levels of the peritoneal fluids of rats as well as the identifi-
cation of compounds in biologically active fractions.
Materials and methods
Plant material
M. officinalis aerial parts were collected from Kızılcahamam,
Ankara in July 2013 and identified by Prof. Dr. Hayri Duman (Gazi
University, Department of Biology, Faculty of Science and Art,
Ankara). A voucher specimen has been kept in the Herbarium of
Faculty of Pharmacy, Gazi University, Ankara, Turkey (GUEF3420).
Preparation of the plant extracts
The aerial parts of M. officinalis (400 g) were dried in the shade
and extracted successively with n-hexane, ethyl acetate (EtOAc)
and methanol (MeOH) for 48 h at room temperature (10  6L).
Solvents were removed under reduced pressure at 40 C to obtain
the extracts. The yields of the n-hexane, ethyl acetate, and meth-
anol extracts were 5, 11, 18%, respectively.
Animals
Non-pregnant six-week-old female Wistar Albino rats (weigh-
ing 200e250 g) were purchased from Kobay Experimental Ani-
mals Laboratory, Ankara, Turkey. The rats were housed according
to the Guide for the Care and Use of Laboratory Animals. The
experimental procedure was approved by the Kobay Experimental
Animals Ethics Committee (Protocol number: 233). The rats were
kept in polysulfone cages at appropriate temperature and hu-
midity. The environment where the rats were housed was under
light-controlled (12-h light/12-h dark) conditions at Kobay Ani-
mals Breeding and Experimental Research Center. All animals
received water and chow ad libitum during the experimental
period. The animals were quarantined for at least 2 weeks and the
estrous cycle was controlled with daily assessment of vaginal
cytology, and rats showing regular estrous cycles were used in this
model.
Induction of endometriosis
The endometriosis rat model was performed according to the
Vernon and Wilson method with some modifications [12]. All the
rats were anesthetized with intramuscular administration of the
combination of 1 mL ketamine (50 mg/mL) and 1 mL xylazine
(20 mg/mL). After anesthesia, the rats were placed in supine posi-
tion and routine antisepsis was conducted for disinfection. A 3-cm
incision was made using a scalpel. The subcutaneous and muscle
layers were separated, and the abdominal cavity was opened. The
right uterine horn was removed, and a 1.5-cm piece of the tissue
was trimmed usingmicroscissors. The trimmed segment was put in
0.9% sodium chloride (normal saline) and longitudinally opened.
The removed endometrial tissue fragment was sutured into the
abdominal wall of the same rat using USP 4/0 polyglactin suture
(Lactasorb PGLA®, Orhan Boz, Turkey). The muscle layers of the
abdomen were closed using USP 3/0 polyglactin suture (Lactasorb
PGLA®, Orhan Boz, Turkey). Another experiment was performed
under anesthesia 28 days after the first operation (Fig. 1).
The areas of endometrial foci were calculated by measuring
their length, width, and height using a micrometer. The equation p/
6 lengthwidth height was used for calculating endometriotic
volumes [13e15]. Furthermore, intra-abdominal adhesions were
scored according to the Blauer's scoring system as follows: 0, no
adhesion; 1, thin adhesions; 2, thick adhesions in one area; 3,
widespread thick adhesions; and 4, adhesions of the internal or-
gans to the abdominal wall [16]. After the all experiments, the
abdomen was closed.
The administration of the extracts and fractions
Thirty rats were divided into five groups, with six rats in each
group to evaluate the activity of extracts whereas thirty-six rats
were randomly divided into six groups to evaluate the activity of
fractions. After the second experiment, 0.5% carboxymethylcellu-
lose (CMC) (control group), extracts of different polarity and frac-
tions were administered orally once a day for 4 weeks. The
reference group received buserelin acetate (20 mg/rat, subcutane-
ously) once per week. The extracts and fractions were applied to
the rats at the dose of 100 mg/kg.
After giving testmaterials to the rats, all rats were sacrificed. The
areas of endometriotic foci, intra-abdominal adhesions, and cyto-
kine levels of the peritoneal fluids were again calculated and
compared with those of the control group.
Techniques for histopathological investigation
Firstly, all endometrium tissues from the normal and experi-
mental groups were fixed with 10% formaldehyde. All tissues were
detected using the Thermo Scientific Excelsior (ES) machine. The
tissues were embedded in paraffin wax and blocks were prepared
using the HistoCentre 2 machine. Subsequently, sections of 3.5 mm
thickness were made from paraffin-embedded blocks using a Leica
RM2255 microtome. The sections were stained with
hematoxylineeosin (HE) using the Shandon Varistan machine.
Photographs of normal and pathological endometrium tissues were
taken using Nikon Eclipse Ci with both polarizing attachment and
Digital Image analysis system, which were then examined under a
light microscope.
Fig. 1. Endometriotic implant view with adhesion. EI: Endometrial implant; B: Bowel.
M. Ilhan et al. / Taiwanese Journal of Obstetrics & Gynecology 59 (2020) 211e219212
Measuring of cytokine levels
The peritoneal fluid was collected to detect the tumor necrosis
factor (TNF)-a, vascular endothelial growth factor (VEGF), and
interleukin (IL)-6 levels in rats. TNF-a, VEGF (Cusabio, USA; catalog
numbers CSB-E11987r and CSB-E04757r), and IL-6 (Bio Source In-
ternational, Nivelles, Belgium; catalog number MBS701221) levels
were quantitatively evaluated using the commercially available
enzyme-linked immunosorbent assay kits according to the manu-
facturer's protocol. After the scarification of animals, the peritoneal
fluid was again collected, and the aforementioned process was
performed. The pre- and post-treatment results were assessed.
Statistical analysis
The results were expressed as mean ± standard error of the
mean (S.E.M.). The ANOVA-Dunnett's test was performed to
determine the significant differences among groups using Graph-
Pad Prism 6.0. p values less than 0.05 were considered significant.
Isolation procedure for the MeOH extract
TheMeOH extract of the plant was subjected to silica gel column
to obtain 41 fractions. The fractions were pooled to get four sub-
fractions (A-D) after thin-layer chromatography analysis using
CHCl3:MeOH (9:1), CHCl3:MeOH:H2O (8:2:0.25), and
EtOAc:CHCl3:MeOH:H2O (6:4:4:1) as the mobile phases. The active
Fractions B and C were subjected to column chromatography over
Sephadex LH-20 and RP-18 silica to obtain pure compounds. The
structural elucidation of the compounds was achieved by their
nuclear magnetic resonance and mass data analyses (Fig. 2).
Results
Biological activity results
The present study investigated the effects of extracts obtained
from the aerial parts of M. officinalis in a surgically-induced endo-
metriosis rat model by evaluating adhesion scores of endometriotic
Fig. 2. Isolated compounds from active fractions of the MeOH extract of M. officinalis.
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implants, areas of endometriotic foci, and cytokine levels of the
peritoneal fluids of rats. Statistically significant difference was not
found in adhesion scores among the extract-treated groups
compared with the control group (Table 1).
Taking into consideration endometriotic implant volumes, the
application of the MeOH extract significantly decreased endo-
metriotic implant volumes from 81.9 to 54.4 mm3. Nevertheless, no
statistically significant difference was observed between groups
treated with other extracts and the control group (Table 2).
In addition to adhesion scores and endometriotic implant vol-
umes, the cytokine levels of the peritoneal fluids were examined.
The application of MeOH extract significantly decreased TNF-a,
VEGF, and IL-6 levels to 5.2, 17.4, and 42.5 pg/mL, respectively.
Although the application of n-hexane and EtOAc extract decreased
the cytokine levels, no statistical difference was noted compared
with the control group (Table 3).
In addition to the MeOH extract, the reference group (buserelin
acetate) also significantly reduced the adhesion scores, endometri-
otic implant volumes, and cytokine levels of the peritoneal fluids.
After the MeOH extract was found to display the remarkable
activity in the rat endometriosis model, it was fractionated using a
silica column to obtain four main fractions (Frs. A-D). The activities
of the four main fractions were also tested in the rat endometriosis
model. Among the fractions obtained from the MeOH extract,
Fractions B and C significantly decreased adhesion scores to 1.9 and
0.9, respectively (Table 1). Furthermore, the endometriotic implant
volumes decreased to 64.9 and 48.3 mm3 in groups treated with
Fractions B and C, respectively (Table 2). Fraction C also significantly
decreased TNF-a, VEGF, and IL-6 levels of the peritoneal fluids,
whereas Fraction B significantly decreased the only IL-6 level of the
peritoneal fluids (Table 3).
Quercetin-3-O-b-D-glucopyranosyl-7-O-a-L-rhamnopyranoside
(1), kaempferol 3-O-b-D-glucopyranosyl-7-O-a-L-rhamnopyrano-
side (2), kaempferol 3-O-a-L-rhamnopyranosyl-(1/6)-b-D-gal-
actopyranosyl-7-O-a-L-rhamnopyranoside (3), and kaempferol 3-
O-a-L-rhamnopyranosyl-(1/2)-[a-L-rhamnopyranosyl-(1/6)]-b-
D-galactopyranosyl-7-O-a-L-rhamnopyranoside (4) were isolated
and identified from Fraction C, which showed higher activity
compared to those of other three fractions. In addition to Fraction C,
Fraction B also significantly decreased adhesion scores and endo-
metriotic implant volumes. Uridine (5), methyl-a-D-fructofurano-
side (6), and melilofficinaside (7) were isolated and identified from
Fraction B.
According to histopathological analyses, whereas a number of
endometrial glands (G) and mononuclear cell infiltration (MCI)
were observed in the control groups, the decrease in G andMCI was
detected in the reference, MeOH extract, Frs. B and C treated
groups. The severity of the lesions was reduced in the n-hexane,
EtOAc, MeOH, and reference groups, respectively (Fig. 3). Histo-
pathological findings showed that the severity of the lesions was
reduced in the Fr D, Fr. A, Fr. B, Fr. C, and reference groups,
respectively (Fig. 4).
NMR data of isolated compounds
Quercetin-3-O-b-D-glucopyranosyl-7-O-a-L-rhamnopyrano-
side (1)d 1H-NMR (400MHz, DMSO): d 7.71 (1H, dd, J¼ 8.4, 2.1 Hz,
H-60), 7.59 (1H, d, J¼ 2.1 Hz, H-20), 6.84 (1H, d, J¼ 8.4 Hz, H-50), 6.79
Table 1
Intraabdominal adhesion scores of the endometriotic implants of extracts and
fractions from MeOH extract prepared from Melilotus officinalis.
Groups Adhesion scores
Pre-treatment Post-treatment
Control 3.1 ± 1.1 3.7 ± 1.0
n-Hexane extract 3.3 ± 0.9 2.6 ± 0.8
EtOAc extract 3.2 ± 0.7 2.2 ± 0.7
MeOH extract 2.9 ± 1.1 1.8 ± 1.1
Reference 3.6 ± 0.5 0.0 ± 0.0***
Control 3.4 ± 0.8 3.8 ± 0.5
Fr. A 3.6 ± 0.3 2.4 ± 1.3
Fr. B 3.1 ± 0.5 1.9 ± 0.9*
Fr. C 3.1 ± 0.6 0.9 ± 0.1**
Fr. D 2.7 ± 1.0 2.6 ± 0.7
Reference 3.5 ± 0.7 0.0 ± 0.0***
*: p < 0.05; **: p < 0.01; ***: p < 0.001; S.E.M.: Standard Error of Mean.
Table 2
Comparison of the pre-treatment and the post-treatment endometriotic implant
volumes.
Material Volume of Endometrioma (mm3) ± S.E.M.
Pre-treatment Post-treatment
Control 98.4 ± 10.7 112.3 ± 14.2
n-Hexane extract 94.5 ± 9.6 86.9 ± 8.2
EtOAc extract 86.1 ± 12.3 71.8 ± 9.9
MeOH extract 81.9 ± 9.9 54.4 ± 7.2**
Reference 96.2 ± 8.7 23.5 ± 3.8***
Control 99.1 ± 10.3 105.3 ± 9.4
Fr. A 98.3 ± 9.9 85.1 ± 8.4
Fr. B 92.6 ± 12.4 64.9 ± 9.1*
Fr. C 96.2 ± 11.9 48.3 ± 6.1***
Fr. D 86.3 ± 8.5 85.7 ± 9.1
Reference 96.8 ± 9.6 25.3 ± 4.2***
**: p < 0.01; ***: p < 0.001; S.E.M.: Standard Error of Mean.
Table 3
Peritoneal TNF-a, VEGF and IL-6 levels before and after treatment in all groups.
Material Peritoneal TNF-a level (pg/ml) Peritoneal VEGF level (pg/ml) Peritoneal IL-6 level (pg/ml)
Pre-treatment Post-treatment Pre-treatment Post-treatment Pre-treatment Post-treatment
Control 12.6 ± 4.5 9.3 ± 3.8 24.6 ± 5.9 26.2 ± 6.3 52.2 ± 9.3 54.7 ± 12.1
n-Hexane extract 9.3 ± 2.7 8.5 ± 2.4 22.5 ± 7.1 19.2 ± 7.2 51.4 ± 11.4 46.2 ± 11.4
EtOAc extract 11.2 ± 3.8 8.4 ± 2.5 26.7 ± 9.3 19.7 ± 11.0 56.3 ± 10.9 47.8 ± 9.3
MeOH extract 10.1 ± 2.5 5.2 ± 0.9* 28.1 ± 8.2 17.4 ± 4.3* 53.5 ± 15.8 42.5 ± 8.1*
Reference 11.3 ± 3.4 1.9 ± 0.4*** 21.5 ± 8.4 9.6 ± 2.3*** 51.2 ± 10.8 24.3 ± 7.4***
Control 16.1 ± 4.7 13.4 ± 6.6 31.4 ± 9.4 28.7 ± 8.3 56.4 ± 10.4 59.1 ± 11.8
Fr. A 17.8 ± 9.5 16.3 ± 8.1 24.7 ± 5.9 24.5 ± 9.1 59.3 ± 10.1 55.1 ± 13.6
Fr. B 14.3 ± 8.9 13.6 ± 6.9 22.5 ± 10.5 19.8 ± 8.6 54.1 ± 7.3 45.6 ± 8.3*
Fr. C 15.3 ± 8.2 3.5 ± 0.9** 26.4 ± 7.5 12.3 ± 4.6** 56.6 ± 11.4 33.9 ± 6.3**
Fr. D 18.3 ± 7.6 19.6 ± 8.8 29.4 ± 9.6 22.5 ± 6.2 52.5 ± 13.7 49.6 ± 11.1
Reference 17.2 ± 6.1 1.2 ± 0.8*** 27.1 ± 7.0 8.8 ± 1.1*** 55.3 ± 9.0 22.5 ± 6.4***
*: p < 0.05; **: p < 0.01; ***: p < 0.001; S.E.M.: Standard Error of Mean.
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(1H, d, J ¼ 2.1 Hz, H-8), 6.44 (1H, d, J ¼ 2.1 Hz, H-6), 5.55 (1H, d,
J ¼ 2.0 Hz, H-1000), 5.41 (1H, d, J ¼ 7.7 Hz, H-100), 3.85e3.02 (the
protons of sugars), 1.13 (3H, d, J ¼ 6.1 Hz, H-6000); 13C-NMR
(100 MHz, DMSO) d 177.7 (C-4), 161.6 (C-7), 160.9 (C-5), 156.8 (C-2),
155.9 (C-9), 148.7 (C-40), 144.9 (C-30), 133.8 (C-3), 122.1 (C-60), 121.0
(C-10), 116.1 (C-20), 115.3 (C-50), 105.6 (C-10), 101.7 (C-100), 99.4 (C-6),
98.5 (C-1000), 94.4 (C-8), 75.9 (C-500), 73.2 (C-300), 71.7 (C-200), 71.2 (C-
4000), 70.3 (C-5000), 70.1 (C-3000), 69.9 (C-400), 68.0 (C-2000), 60.2 (C-600),
18.0 (C-6000). HRESIMS: m/z ¼ 611.1606 [MþH]þ (calcd. 611.1612 for
C27H31O16).
Kaempferol 3-O-b-D-glucopyranosyl-7-O-a-L-rhamnopyr-
anoside (2)d 1H-NMR (500 MHz, CD3OD): d 8.11 (2H, d, J¼ 8.7 Hz,
H-20, 60), 6.89 (2H, d, J¼ 8.7 Hz, H-30, 50), 6.75 (1H, d, J¼ 2.1 Hz, H-8),
6.46 (1H, d, J ¼ 2.1 Hz, H-6), 5.57 (1H, d, J ¼ 1.8 Hz, H-1000), 5.20 (1H,
d, J ¼ 7.7 Hz, H-100), 4.02e3.45 (the protons of sugars), 1.25 (3H, d,
J ¼ 6.2 Hz, H-6000); 13C-NMR (125 MHz, CD3OD) d 179.8 (C-4), 163.6
(C-7), 162.8 (C-5), 161.8 (C-40), 159.6 (C-2), 158.0 (C-9), 135.7 (C-3),
132.5 (C-20, 60), 122.5 (C-10), 116.2 (C-30, 50), 107.3 (C-10), 104.6 (C-
100), 100.6 (C-6), 99.8 (C-1000), 95.6 (C-8), 77.2 (C-500), 74.9 (C-300), 73.6
(C-200), 73.0 (C-4000), 72.0 (C-400), 71.7 (C-3000), 71.3 (C-2000), 70.0 (C-5000),
Fig. 3. Histopathological views of all extracts-treated groups. (A): Control group, Original magnification was 10, HE (B): n-Hexane extract-treated group, Original magnification
was 10, HE (C): EtOAc extract-treated group, Original magnification was 40, HE (D): MeOH extract-treated group, Original magnification was 40, HE (E): Reference group,
Original magnification was 40, HE Arrow pointed abbreviation: G: Endometrial gland; F: Fibroblast; MCI: Mononuclear cell infiltration; C: Collagen; E: Endometrial gland
epithelium; BV: Blood Vessel; DG: Degenerative endometrial glands; DC: Degenerative collagen fibers.
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62.0 (C-600), 18.1 (C-6000). HRESIMS: m/z ¼ 595.1657 [MþH]þ (calcd.
595.1663 for C27H31O15).
Kaempferol 3-O-a-L-rhamnopyranosyl-(1/6)-b-D-gal-
actopyranosyl-7-O-a-L-rhamnopyranoside (3) d 1H-NMR
(400 MHz, DMSO): d 8.10 (2H, d, J ¼ 8.8 Hz, H-20, 60), 6.88 (2H, d,
J ¼ 8.8 Hz, H-30, 50), 6.81 (1H, d, J ¼ 2.2 Hz, H-8), 6.45 (1H, d,
J¼ 2.2 Hz, H-6), 5.56 (1H, d, J¼ 1.8 Hz, H-1000'), 5.36 (1H, d, J¼ 7.7 Hz,
H-100), 4.41 (1H, d, J ¼ 1.6 Hz, H-1000), 3.86e3.09 (the protons of
sugars), 1.13 (3H, d, J ¼ 6.1 Hz, H-6000'), 1.07 (3H, d, J ¼ 6.1 Hz, H-6000);
13C-NMR (100 MHz, DMSO) d 177.7 (C-4), 161.7 (C-7), 160.8 (C-5),
160.3 (C-40), 157.1 (C-2), 156.1 (C-9), 133.6 (C-3), 131.1 (C-20, 60),
120.7 (C-10), 115.2 (C-30, 50), 105.6 (C-10), 99.4 (C-6), 94.7 (C-8), 7-
rha: 98.5 (C-1), 71.7 (C-4), 70.3 (C-3), 70.1 (C-2), 69.9 (C-5), 17.8
(C-6), 3-gal: 101.9 (C-1), 73.7 (C-5), 73.0 (C-3), 71.1 (C-2), 68.3 (C-4),
65.3 (C-6), Rha (C-6 of gal): 100.1 (C-1), 72.0 (C-4), 70.6 (C-3), 70.4
(C-2), 68.0 (C-5), 17.9 (C-6). HRESIMS: m/z ¼ 741.2229 [MþH]þ
(calcd. 741.2242 for C33H41O19).
Kaempferol 3-O-a-L-rhamnopyranosyl-(1/2)-[a-L-rhamno-
pyranosyl-(1/6)]-b-D-galactopyranosyl-7-O-a-L-rhamnopyr-
anoside (4)d 1H-NMR (500MHz, CD3OD): d 8.09 (2H, d, J¼ 8.9 Hz,
H-20, 60), 6.87 (2H, d, J¼ 8.9 Hz, H-30, 50), 6.73 (1H, d, J¼ 2.2 Hz, H-8),
6.46 (1H, d, J ¼ 2.2 Hz, H-6), 5.60 (1H, d, J ¼ 7.7 Hz, H-100), 5.56 (1H,
Fig. 4. Histopathological views of all fractions-treated groups. (A): Control group, Original magnification was 10, HE (B): Fraction A-treated group, Original magnification was 40,
HE (C): Fraction B-treated group, Original magnification was 40, HE (D): Fraction C-treated group, Original magnification was 4, HE (E): Fraction D-treated group, Original
magnification was 10, HE (F): Reference group, Original magnification was 40, HE Arrow pointed abbreviation: G: Endometrial gland; F: Fibroblast; MCI: Mononuclear cell
infiltration; C: Collagen; E: Endometrial gland epithelium; BV: Blood Vessel; DG: Degenerative endometrial glands; DC: Degenerative collagen fibers; S: Stroma.
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d, J ¼ 1.7 Hz, H-1000''), 5.23 (1H, d, J ¼ 1.6 Hz, H-1000'), 4.52 (1H, d,
J ¼ 1.6 Hz, H-1000), 4.01e3.27 (the protons of sugars), 1.26 (3H, d,
J ¼ 6.1 Hz, H-6000'), 1.17 (3H, d, J ¼ 6.3 Hz, H-6000''), 0.99 (3H, d,
J ¼ 6.3 Hz, H-6000); 13C-NMR (125 MHz, CD3OD) d 179.5 (C-4), 163.3
(C-7), 162.9 (C-5), 162.9 (C-40), 159.5 (C-2), 157.9 (C-9), 134.5 (C-3),
132.4 (C-20, 60), 121.7 (C-10), 116.9 (C-30, 50), 107.4 (C-10), 100.4 (C-6),
95.6 (C-8), 7-rha: 99.9 (C-1), 73.6 (C-4), 72.1 (C-3), 71.7 (C-2), 71.2
(C-5), 18.1 (C-6), 3-gal: 100.8 (C-1), 77.5 (C-2), 75.8 (C-3), 75.4 (C-5),
70.7 (C-4), 67.1 (C-6), Rha (C-6 of gal): 101.8 (C-1), 73.9 (C-4), 72.2
(C-3), 72.1 (C-2), 69.7 (C-5), 17.9 (C-6), Rha (C-2 of gal): 102.6 (C-1),
74.0 (C-4), 72.4 (C-2), 72.3 (C-3), 69.9 (C-5), 17.6 (C-6). HRESIMS:m/
z ¼ 887.2826 [MþH]þ (calcd. 887.2821 for C39H51O23).
Uridine (5) d 1H-NMR (400 MHz, CD3OD): d 8.01 (1H, d,
J¼ 8.0 Hz, H-6), 5.90 (1H, d, J¼ 4.7 Hz, H-10), 5.70 (1H, d, J¼ 8.0 Hz,
H-5), 4.18 (1H, t, J ¼ 4.7 Hz, H-20), 4.15 (1H, t, J ¼ 4.7 Hz, H-30), 4.01
(1H, m, H-40), 3.84 (1H, dd, J ¼ 12.2, 2.7 Hz, H-50b), 3.73 (1H, dd,
J ¼ 12.2, 3.2 Hz, H-50a); 13C-NMR (100 MHz, CD3OD) d 166.2 (C-4),
152.5 (C-2), 142.8 (C-6), 102.7 (C-5), 90.8 (C-10), 86.4 (C-40), 75.8 (C-
20), 71.4 (C-30), 62.3 (C-60). HRESIMS:m/z¼ 451.1613 [MþH]þ (calcd.
451.1604 for C9H13N2O6).
Methyl-a-D-fructofuranoside (6) d 1H-NMR (400 MHz,
CD3OD): d 4.05 (1H, d, J ¼ 4.1 Hz, H-3), 3.92 (1H, m, H-4), 3.87 (1H,
m, H-5), 3.78 (1H, dd, J ¼ 12.0, 1.8 Hz, H-6b), 3.74 (1H, dd, J ¼ 12.0,
5.1 Hz, H-6a), 3.66 (1H, d, J ¼ 11.9 Hz, H-1b), 3.65 (1H, d, J¼ 11.9 Hz,
H-1a), 3.33 (3H, s, OCH3); 13C-NMR (100MHz, CD3OD) d 109.2 (C-2),
84.6 (C-5), 82.6 (C-3), 78.9 (C-4), 62.8 (C-6), 60.5 (C-1), 48.9 (OCH3).
HRESIMS: m/z ¼ 195.0859 [MþH]þ (calcd. 195.0868 for C7H15O6).
Melilofficinaside (7) d 1H-NMR (500 MHz, pyridine): d 7.55
(1H, dd, J ¼ 8.3 Hz, 1.9 Hz, H-5), 7.21 (1H, d, J ¼ 8.1 Hz, H-60), 7.11
(1H, dd, J ¼ 8.3 Hz, 2.3 Hz, H-6), 7.09 (1H, d, J ¼ 2.3 Hz, H-8), 6.71
(1H, d, J ¼ 2.3 Hz, H-30), 6.59 (1H, dd, J ¼ 8.1 Hz, 2.3 Hz, H-50), 5.67
(1H, d, J ¼ 7.2 Hz, H-100), 5.58 (1H, dd, J ¼ 7.8 Hz, 1.9 Hz, H-4), 4.28
(1H, m, H-2), 3.72 (1H, m, H-2), 3.67 (3H, s, OCH3), 3.57 (1H, m, H-
3); 13C-NMR (125 MHz, pyridine) d 162.0 (C-40), 161.7 (C-20), 160.2
(C-7), 157.5 (C-9), 132.9 (C-5), 125.8 (C-60), 120.2 (C-10), 115.1 (C-10),
111.5 (C-6), 107.0 (C-50), 105.6 (C-8), 97.6 (C-30), 79.2 (H-4), 67.2 (C-
2), 55.8 (C-40-OCH3), 40.4 (C-3); sugar moiety: 102.4 (C-100), 79.3 (C-
300), 78.8 (C-500), 75.2 (C-200), 71.5 (C-400), 62.6 (C-600). HRESIMS: m/
z ¼ 451.1613 [MþH]þ (calcd. 451.1604 for C22H27O10).
Discussion
M. officinalis is commonly used for the treating ulcers of the
eyes, earache, bronchitis, hemorrhoids, kidney stones, and painful
menstruation, swelling and hardening of uterus [3,4]. The European
Medicines Agency reported the use of M. officinalis orally against
stomach ache, gastric ulcer, and disorders of liver and uterus in folk
medicine [5].
Previous studies reported that M. officinalis has some biological
activities such as the antioxidant, antiproliferative and anti-
inflammatory effects [6,7]. Pastorino et al. also showed that
M. officinalis promoted tissue regeneration, prevented skin aging,
and reduced fat deposition [8].
Endometriosis is a disease defined by the availability and
growth of endometrial tissue outside the uterus, especially into the
peritoneum. Some biological changes, such as local
inflammatoryereparative phenomena and involvement of periph-
eral bloodmononuclear cells, are observed in the peritoneal fluid of
women with endometriosis [17]. Pizzo et al. (2002) reported that
the peritoneal fluid levels of TNF-a were extremely high in early
stage [18]. The other study demonstrated that the levels of cyto-
kines including VEGF, IL-6, IL-1b and TNF-a were higher in women
with endometriosis, indicating their role in the pathogenesis of
endometriosis [19]. However, no significant difference was
observed in the serum levels of IL-5, IL-7, and IL-12 between
womenwith endometriosis and healthy women [20]. Koyama et al.
(1993) found that the levels of IL-5 and IL-6, but not IL-1, were
related to endometriosis [21]. Li et al. (2017) showed that disorders
involving IL-6 and IL-6 receptors were correlated with the etiology
of endometriosis. An increase in the IL-6 soluble receptor in the
peritoneal fluid promoted the development of endometriosis by
enhancing the bioactivity of IL-6 [22]. In the light of these in-
formations, the cytokine levels in the peritoneal fluids were eval-
uated in the present study. According to the results, the cytokine
levels decreased in the MeOH extractetreated and reference
groups.
Sex steroids such as progesterone and estrogen are essentially
produced in the ovaries and these type hormones cause the growth
of endometrial tissue, basically by stimulating and inhibiting cell
proliferation. Furthermore, estrogen plays a significant role in the
regulation of cyclic gonadotropin release and in folliculogenesis
[23]. Collins-Burow et al. (2000) reported that some flavonoids
possess antiestrogenic activity as well as estrogenic activity. The
antiestrogenic activities of flavonoids such as apigenin, luteolin,
kaempferide are more than their estrogenic activities [24].
Furthermore, flavonoids decrease the expression and secretion of
cytokines [25]. Another study showed that apigenin inhibited TNF-
a-induced cell proliferation and reduced the mitogenic activity and
inflammatory response in endometriotic stromal cells [26]. Api-
genin was similarly stated to inhibit the proliferation and tumori-
genesis of human ovarian cancer A2780 cells in vitro and might
serve as a substitute compound for treating endometrial cancer in
postmenopausal women [27].
Endometriotic lesions are qualified by a deep vascularization
that occurs through angiogenesis process [28e31]. VEGF which is
one of the most potent angiogenic factors is postulated to be
involved in the progress of the ectopic lesions in endometriosis
[32,33]. Vascularization and VEGF and its receptor expression are
mainly high in deeply infiltrating endometriosis. Those situations
supported that the antiangiogenic therapy contribute to the
regression of endometriosis. Kim (2003) searched the anti-
angiogenic potential of flavonoids. Their results reported that the
flavonoids displayed antiangiogenic effect preventing VEGF/basic
fibroblast growth factor-induced matrix metalloproteinase (MMP)-
1 and the activation of pro-MMP-2 [34]. Another study conducted
by Wu et al. (2012) showed that the flavonoid extract including
some quercetin and kaempferol derivatives were active in inhibit-
ing expression of intercellular adhesion molecule-1 and vascular
cell adhesion molecule induced by TNF-a in human umbilical vein
endothelial cells [35]. Previous studies reported that quercetin
showed antiangiogenic effect by decreasing the phosphorylation
and mRNA expression of VEGF receptor (VEGFR)-2, the expression
of cyclooxygenase (COX)-2 and the secretion of MMP-2 andMMP-9
[36e40]. Kaempferol also displayed antiangiogenic effect by
reducing VEGF secretion, VEGF mRNA and protein expression,
MMP-2 and MMP-9 activity [41e43]. Another studies which is
about the antiangiogenic effects of flavonoids exhibited that api-
genin inhibited Smad2/3 and Src/FAK/AKT pathways, IL-6/STAT3
pathway, mRNA and protein expression of IL-6, IL-8 and
decreased MMP-2 and -9 activities [44e46].
In the present study, Fraction C obtained from the MeOH extract
showed thehighest activity in the rat endometriosismodel, and four
glycosylated flavonoids were isolated from this fraction. Based on
the findings of previous studies and the present study, it was sug-
gested that theMeOHextract of the aerial parts ofM. officinalis could
be used to treat endometriosis due to its glycosylated flavonoids.
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Conclusions
This novel study described the role of M. officinalis against
endometriosis. The present study proved the traditional use of the
aerial parts of M. officinalis in endometriosis. Four flavonoid gly-
cosides (1e4) were isolated as the main components of the active
fraction, whichmight be responsible for the activity of plant extract
in the endometriosis rat model. In addition, compounds 5e7 were
isolated from Fraction B which showed moderate activity. There-
fore, the effect of the extract could be attributed to glycosylated
flavonoids. Furthermore, the authors think that the action mecha-
nism of glycosylated flavonoids is due to their antiangiogenic
properties. In further studies, we are planning to conduct the dose-
effect studies in the rat endometriosis model.
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